956100-62-2

Basic information

• Product Name: 4-Amino-8-bromo-2-chloroquinazoline
• Synonyms: 2-Chloro-4-aMino-8-broMoquinazoline;8-Bromo-2-chloro-quinazolin-4-ylamine;4-Amino-8-bromo-2-chloroquinazoline
• CAS NO: 956100-62-2
• Molecular Formula: C₈H₅BrClN₃
• Molecular Weight: 258.505
• Mol File: 956100-62-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-Amino-8-bromo-2-chloroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-8-bromo-2-chloroquinazoline(956100-62-2)
• EPA Substance Registry System: 4-Amino-8-bromo-2-chloroquinazoline(956100-62-2)

Safety Data

• Hazardous Substances Data: 956100-62-2(Hazardous Substances Data)

Usage

General Description

4-Amino-8-bromo-2-chloroquinazoline is a chemical compound with the molecular formula C10H6BrClN3. It is a heterocyclic compound that contains a quinazoline ring, and is substituted with an amino group at the 4-position, a bromine atom at the 8-position, and a chlorine atom at the 2-position. 4-Amino-8-bromo-2-chloroquinazoline has potential applications in medicinal chemistry, particularly in the development of pharmaceutical drugs as it exhibits biological activity. It may also be used as a building block in the synthesis of other complex organic compounds. Additionally, it has been studied for its potential use in materials science and organic electronics.

Upstream product

• 331646-99-2 8-bromoquinazoline-2,4-diol 
• 331646-99-2 8-bromoquinazoline-2,4-(1H,3H)-dione 
• 20776-51-6 2-amino-3-bromo benzoic acid 
• 331647-05-3 8-bromo-2,4-dichloroquinazoline 

Downstream Products

• 956100-63-3 8-bromo-2-chloroquinazoline 

Relevant articles and documents

BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS

Provided herein are modulators of beta-adrenergic receptors.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.